Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 10, 2004, Pages 3817-3822

  Hagens, Steven ^a,c   Habel, André ^b   Von Ahsen, Uwe ^b   Von Gabain, Alexander ^b   Bläsi, Udo ^a  

^a Vienna Biocenter   (Austria)

^b INTERCELL AG   (Austria)

^c ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; ENDOTOXIN; RESTRICTION ENDONUCLEASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL CELL WALL; BACTERIOLYSIS; BACTERIOPHAGE; GENE TARGETING; GRAM NEGATIVE INFECTION; INFLAMMATION; LETHAL DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESTRICTION MAPPING; SEPTICEMIA; SURVIVAL RATE; TARGET CELL; WILD TYPE;

ANIMALS; BACTERIOPHAGE PF1; ENDOTOXINS; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; ORGANISMS, GENETICALLY MODIFIED; PLASMIDS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA; VIRUS REPLICATION;

EID: 4644257971     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.10.3817-3822.2004     Document Type: Article

References (38)

1. Agelaki, S., C. Tsatsanis, A. Gravanis, and A. N. Margioris. 2002. Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. Infect. Immun. 70:6068-6074.
2. Anton, B. P., D. F. Heiter, J. S. Benner, E. J. Hess, L. Greenough, L. S. Moran, B. E. Slatko, and J. E. Brooks. 1997. Cloning and characterization of the BglII restriction-modification system reveals a possible evolutionary footprint. Gene 187:19-27.
3. Barrow, P. A., and J. S. Soothill. 1997. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 5:268-271.
4. Berchieri, A., Jr., M. A. Lovell, and P. A. Barrow. 1991. The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium. Res. Microbiol. 142:541-549.
5. Biswas, B., S. Adhya, P. Washart, B. Paul, A. N. Trostel, B. Powell, R. Carlton, and C. R. Merril. 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 70:204-210.
6. Bodey, G. P., R. Bolivar, V. Fainstein, and L. Jadeja. 1983. Infections caused by Pseudomonas aeruginosa. Rev. Infect. Dis. 5:279-313.
7. Bradley, D. E. 1973. The adsorption of Pseudomonas aeruginosa filamentous bacteriophage Pf to its host. Can. J. Microbiol. 19:623-631.
8. Brosius, J. 1989. Superpolylinkers in cloning and expression vectors. DNA 8:759-777.
9. Coopersmith, C. M., D. M. Amiot, P. E. Stromberg, W. M. Dunne, C. G. Davis, D. F. Osborne, K. D. Husain, I. R. Turnbull, R. S. Hothkiss, and T. G. Buchman. 2003. Antibiotics improve survival and alter the inflammatory profile in a murine model of sepsis from Pseudomonas aeruginosa pneumonia. Shock 19:408-418.
10. Hagens, S., and U. Bläsi. 2003. Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett. Appl. Microbiol. 37:318-323.
11. Heumann, D., and T. Roger. 2002. Initial responses to endotoxins and Gram-negative bacteria. Clin. Chim. Acta 323:59-72.
12. Jobling, M. G., and R. K. Holmes. 1990. Construction of vectors with the p15a replicon, kanamycin resistance, inducible lacZ alpha and pUC18 or pUC19 multiple cloning sites. Nucleic Acids Res. 18:5315-5353.
13. Kasmann, L. A., A. Kasman, C. Westwater, J. Dolan, M. G. Schmidt, and J. S. Norris. 2002. Overcoming the phage replication threshold: a mathematical model with implications for phage therapy. J. Virol. 76:5557-5564.
14. Kruzel, M. L., Y. Harari, D. Mailman, J. K. Actor, and M. Zimecki. 2002. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS induced inflammatory response in mice. Clin. Exp. Immunol. 130:25-31.
15. Lepper, P. M., T. K. Held, E. M. Schneider, E. Bolke, H. Gerlach, and M. Trautmann. 2002. Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med. 28:824-833.
16. Levin, B. R., and J. J. Bull. 1996. Phage therapy revisited: the poulation biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am. Nat. 147:881-898.
17. Luiten, R. G., D. G. Putterman, J. G. Schoenmakers, R. N. Konings, and L. A. Day. 1985. Nucleotide sequence of the genome of Pf3, an IncP-1 plasmid-specific filamentous bacteriophage of Pseudomonas aeruginosa. J. Virol. 56:268-276.
18. Marinus, M. G., M. Carraway, A. Z. Frey, L. Brown, and J. A. Arraj. 1983. Insertion mutations in the dam gene of Escherichia coli K-12. Mol. Gen. Genet. 192:288-289.
19. Marzari, R., D. Sblattero, M. Righi, and A. Bradbury. 1997. Extending filamentous phage host range by the grafting of a heterologous receptor binding domain. Gene 185:27-33.
20. Merril, C. R., B. Biswas, R. Carlton, N. C. Jensen, G. J. Creed, S. Zullo, and S. Adhya. 1996. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. USA 93:3188-3192.
21. Merril, C. R., D. Scholl, and S. L. Adhya. 2003. The prospect for bacteriophage therapy in Western medicine. Nat. Rev. Drug Discov. 2:489-497.
22. Nakamura, A., Y. Mori, K. Hagiwara, T. Suzuki, T. Sakakibara, T. Kikuchi, T. Igarashi, M. Ebina, T. Abe, J. Miyazaki, T. Takai, and T. Nukiwa. 2003. Increased susceptibility to LPS-induced toxic shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J. Exp. Med. 5:669-674.
23. O'Brien, A. D., L. R. Marques, C. F. Kerry, J. W. Newland, and R. K. Holmes. 1989. Shiga-like toxin converting phage of enterohemorrhagic Escherichia coli strain 933. Microb. Pathog. 6:381-390.
24. Purswani, M. U., S. J. Eckert, H. K. Arora, and G. J. Noel. 2002. Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model. J. Antimicrob. Chemother. 50:51-58.
25. Rietsch, A., and U. Bläsi. 1993. Non-specific hole formation in the Escherichia coli inner membrane by λ S proteins is independent of cellular secY and secA functions and of the proportion of membrane acidic phospholipids. FEMS Microbiol. Lett. 107:101-106.
26. Riffenburgh, R. H. 1999. Statistics in medicine. Academic Press, Inc., San Diego, Calif.
27. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
28. Shalaby, M. R., A. Waage, L. Aarden, and T. Espevik. 1989. Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo. Clin. Immunol. Immunopathol. 53:488-498.
29. Slopek, S., I. Durlakowa, B. Weber-Dabrowska, A. Kucharewicz-Krukowska, M. Dabrowski, and R. Bisikiewicz. 1983. Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch. Immunol. Ther. Exp. (Warsaw) 31:267-291.
30. Smith, H. W., and M. B. Huggins. 1982. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128:307-318.
31. Soothill, J. S. 1992. Treatment of experimental infections of mice with bacteriophages. J. Med. Microbiol. 37:258-261.
32. Stanisich, V. A. 1974. The properties and host range of male-specific bacteriophages of Pseudomonas aeruginosa. J. Gen. Microbiol. 84:332-342.
33. Sulakvelidze, A., Z. Alavidze, and J. G. Morris, Jr. 2001. Bacteriophage therapy. Antimicrob. Agents Chemother. 45:649-659.
34. Waldor, M. K., and J. J. Mekalanos. 1996. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science 272:1910-1914.
35. West, S. E., H. P. Schweizer, C. Dall, A. K. Sample, and L. J. Runyen-Janecky. 1994. Construction of improved Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in Pseudomonas aeruginosa. Gene 148:81-86.
36. Westwater, C., L. M. Kasman, D. A. Schofield, P. A. Werner, J. W. Dolan, M. G. Schmidt, and J. S. Norris. 2003. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother. 47:1301-1307.
37. Yagel, S., J. F. Barrett, D. J. Amaratunga, and M. B. Frosco. 1996. In vivo oral efficiacy of levofloxacin for treatment of Pseudomonas aeruginosa infections in a murine model of septicemia. Antimicrob. Agents Chemother. 40:2894-2897.
38. Young, R., and U. Bläsi. 1995. Holins: form and function in bacteriophage lysis. FEMS Microbiol. Rev. 17:191-205.